靶向丙酮酸激酶M2的PET探针[18F]DASA-23在人体内的生物分布与辐射剂量学研究
本研究在5名健康志愿者中评估了新型PET显像剂[18F]DASA-23的安全性、生物分布与辐射剂量学。志愿者静脉注射295.0 ± 8.2 MBq后行脑动态扫描及全身PET/MRI扫描至注射后3小时,结果显示示踪剂可被动透过血脑屏障并快速清除,胆囊、肝脏、小肠和膀胱摄取较高,有效剂量为23.5 ± 5.8 μSv/MBq,未出现不良反应。
要点
- 5名健康志愿者均耐受[18F]DASA-23 PET/MRI检查,无不良反应。
- [18F]DASA-23可被动穿过血脑屏障,随后从脑内快速清除。
- 胆囊、肝脏、小肠和膀胱摄取高,提示肝胆与泌尿清除,有效剂量23.5 ± 5.8 μSv/MBq。
核心结论
- 研究成功完成了[18F]DASA-23的首次人体先导试验,结果提示该示踪剂可安全用于人体以评估丙酮酸激酶M2水平。
- 正在进行的研�究正在评估[18F]DASA-23显示颅内恶性肿瘤的能力(NCT03539731)。
研究设计与样本
- 研究纳入5名签署书面知情同意书的健康志愿者,静脉注射295.0 ± 8.2 MBq的[18F]DASA-23。
- 注射后立即行脑动态扫描15分钟,随后行系列全身PET/MRI扫描至注射后3小时。
- 定期采集血样并在示踪剂给药前后监测生命体征,勾画多个器官感兴趣区、计算时间-放射性曲线,并用OLINDA/EXM(1.1版)软件估算器官摄取与剂量学。
主要发现
- 所有受试者均耐受PET/MRI检查,对[18F]DASA-23无不良反应。
- [18F]DASA-23被动穿过血脑屏障,随后从脑内快速清除。
- 胆囊、肝脏、小肠和膀胱等处可见[18F]DASA-23高蓄积,提示肝胆与泌尿清除途径。
- [18F]DASA-23的有效剂量为23.5 ± 5.8 μSv/MBq。
关键数值与推荐
- 有效剂量为23.5 ± 5.8 μSv/MBq。
- 注射活度为295.0 ± 8.2 MBq。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the safety, biodistribution, and radiation dosimetry of the novel positron emission tomography (PET) radiopharmaceutical 1-((2-fluoro-6-[[18F]]fluorophenyl)sulfonyl)-4-((4-methoxyphenyl)sulfonyl)piperazine ([18F]DASA-23) in healthy volunteers. METHODS: We recruited 5 healthy volunteers who provided a written informed consent. Volunteers were injected with 295.0 ± 8.2 MBq of [18F]DASA-23 intravenously. Immediately following injection, a dynamic scan of the brain was acquired for 15 min. This was followed by serial whole-body PET/MRI scans acquired up to 3 h post-injection. Blood samples were collected at regular intervals, and vital signs monitored pre- and post-radiotracer administration. Regions of interest were drawn around multiple organs, time-activity curves were calculated, and organ uptake and dosimetry were estimated with OLINDA/EXM (version 1.1) software. RESULTS: All subjects tolerated the PET/MRI examination, without adverse reactions to [18F]DASA-23. [18F]DASA-23 passively crossed the blood-brain barrier, followed by rapid clearance from the brain. High accumulation of [18F]DASA-23 was noted in organs such as the gallbladder, liver, small intestine, and urinary bladder, suggesting hepatobiliary and urinary clearance. The effective dose of [18F]DASA-23 was 23.5 ± 5.8 μSv/MBq. CONCLUSION: We successfully completed a pilot first-in-human study of [18F]DASA-23. Our results indicate that [18F]DASA-23 can be used safely in humans to evaluate pyruvate kinase M2 levels. Ongoing studies are evaluating the ability of [18F]DASA-23 to visualize intracranial malignancies, NCT03539731. TRIAL REGISTRATION: ClinicalTrials.gov , NCT03539731 (registered 28 May 2018).
引用
- Beinat C, Patel CB, Haywood T, et al. Human biodistribution and radiation dosimetry of [18F]DASA-23, a PET probe targeting pyruvate kinase M2. Eur J Nucl Med Mol Imaging. 2020. PMID: 31938892. doi:10.1007/s00259-020-04687-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。